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Abstract
Background: Arabinogalactan from Larch tree (Larix spp.) bark has previously demonstrated immunostimulatory
activity. The purpose of this study was to test the hypothesis that ingestion of a proprietary arabinogalactan
extract, ResistAid™, would selectively enhance the antibody response to the pneumococcal (pneumonia) vaccine in
healthy adults.
Methods: This randomized, double-blind, placebo-controlled, parallel group pilot study included 45 healthy adults
who had not previously been vaccinated against Streptococcus pneumoniae. The volunteers began taking the study
product or placebo (daily dosage 4.5 g) at the screening visit (V1-Day 0) and continued over the entire 72 day
study period. After 30 days the subjects received the 23-valent pneumococcal vaccine (V2). They were monitored
the following day (V3-Day 31), as well as 21 days (V4-Day 51) and 42 days (V5-Day 72) after vaccination. Responses
by the adaptive immune system (antigen specific) were measured via pneumococcal IgG antibodies (subtypes 4,
6B, 9V, 14, 18C, 19F, and 23F) and salivary IgA levels. Responses by the innate immune system (non-specific) were
measured via white blood cell counts, inflammatory cytokines and the complement system.
Results: Vaccination significantly increased pneumococcal IgG levels as expected. The arabinogalactan group
demonstrated a statistically significant greater IgG antibody response than the placebo group in two antibodies
subtypes (18C and 23F) at both Day 51 (p = 0.006 and p = 0.002) and at Day 72 (p = 0.008 and p = 0.041). These
same subtypes (18C and 23F) also demonstrated change scores from baseline which were significant, in favor of
the arabinogalactan group, at Day 51 (p = 0.033 and 0.001) and at Day 72 (p = 0.012 and p = 0.003). Change
scores from baseline and mean values were greater in the arabinogalactan group than placebo for most time
points in antibody subtypes 4, 6B, 9V, and 19F, but these differences did not reach statistical significance. There
was no effect from the vaccine or arabinogalactan on salivary IgA, white blood cell count, inflammatory cytokines
or complement.
Conclusions: The proprietary arabinogalactan extract (ResistAid™), tested in this randomized, double-blind,
placebo-controlled, parallel-group pilot study, increased the antibody response of healthy volunteers to the
23-valent pneumococcal vaccine compared to placebo.
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The immune system is a highly complex orchestration of
cells, organs, tissues and active molecules which interact
in an elaborate and dynamic network to protect the body
from infection. The immune system can be divided into
two categories: the innate immune system and the adap-
tive immune system. Innate immunity is an immediate
but non-specific response. Adaptive or acquired immu-
nity involves a specific reaction to a pathogen which the
immune system recognizes from a previous encounter.
The process of acquired immunity is the basis for vacci-
nation[1]. Recent research has focused on the role of
nutrition (foods and specific components of foods) in the
responsiveness of the immune system to challenges. Vac-
cine-specific serum antibody production has been sug-
gested as a highly suitable model to evaluate dietary
intervention on the resistance to infection or to other
immune system-related diseases[2].
The pneumococcal vaccine can reduce the incidence
and/or severity of infections caused by Streptococcus
pneumoniae: namely, pneumonia, otitis media, sinusitis
and meningitis. The 23-valent vaccine contains 23 pneu-
mococcal polysaccharide antigens (serotypes 1, 2, 3, 4, 5,
6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C,
19A, 19F, 20, 22F, 23F and 33F[3]. Although there are
at least 90 distinct serotypes, these 23 serotypes
accounted for 85% to 90% of invasive pneumococcal
infections in the US[3]. The 23-valent vaccine produces
a humoral (antibody-mediated) response: inducing the
production of antibody from B-lymphocytes in the
absence of help from T-lymphocytes. The type and con-
centration of antibody produced is dependent on the
site of exposure. Systemic administration results primar-
ily in the generating of circulating immunoglobulin(Ig)G
whereas mucosal antigenic challenge results in a more
vigorous IgA response[1]. In contrast to the 23-valent
pneumococcal vaccine, a 7-valent vaccine conjugated to
a nontoxic diphtheria protein (used for children younger
than 5 years) will induce a T-cell response[3].
Studies on improvement of the response to the pneu-
mococcal vaccine by adults include revaccination, the
addition on conjugates to the vaccine and alternative
antigenic substances[4]. In addition, nutritional products
have been tested on their effect on the response to vac-
cination. Supplementation with 200 mg/day vitamin E
for 4 months to subjects at least 65 years of age caused
a suggestive, but insignificant, increase in antibody
response to the pneumococcal vaccine[5]. Another study
evaluated the effects of prebiotic fructo-oligosaccharides
(70% raftilose and 30% raftiline) derived from inulin on
the response by an elderly population (70 years old and
above). In this study the response to vaccination with
the influenza B and pneumococcal vaccines was not
significantly increased[6].
Arabinogalactans are high molecular weight, highly
branched, water-soluble polysaccharides, which contain
units of D-galactose and L-arabinose[7]. Arabinogalac-
tans have previously demonstrated immunostimulatory
activity[8,9]. They are present in several immune-enhan-
cing herbs, including Echinacea purpurea, Baptisia tinc-
toria, Thuja occidentalis, Angelica acutiloba, and
Curucuma longa and the medicinal mushroom Gano-
derma lucidum.[10-12]. Arabinogalactans from Larch
(Larix spp.) have been shown to stimulate natural killer
cell cytotoxicity in vitro through the generation of inter-
feron gamma and inhibit the metastasis of tumor cells
to the liver in a rodent model[7,13,14]. A dog study
demonstrated increases in white blood cell counts (due
to increases in neutrophils and eosinophils), and no
effect on serum IgG, IgM or IgA following oral admin-
stration indoses of 0.55 g/day or 1.65 g/day for 10 days
[15]. A randomized, double-blind, placebo-controlled
study evaluated the immunomodulating effects of a pre-
paration of proprietary larch arabinogalactan (1.5 g/day)
alone, and in combination with various preparations of
Echinacea: an extract of Echinacea purpurea whole herb
containing 4% phenolic compound (1.5 g/day), a pre-
paration of E. purpurea w h o l eh e r ba n dap r e p a r a t i o n
E. angustifolia root (36 to 680 mg/day)[16]. The study
included 48 adult women who were divided into six
groups of eight women. After 4 weeks of treatment,
complement properdin increased by 18% in the group
that received all four preparations and by 21% in the
group given preparations of both species of Echinacea.
The current human clinical pilot study was designed
to test the hypothesis that the ingestion of Resistaid™,a
proprietary arabinogalactan extracted from Larch (Larix
laricina), would selectively enhance the antibody
response by adults to the 23-valent pneumococcal vac-
cine. Indications that the product would have immunos-
timulatory activity came from previous studies
conducted with this proprietary product[15,16]. As there
was no prior human data regarding the ability of this
proprietary arabinogalactan extract to impact the
immune response to the pneumococcal vaccine, a power
calculation could not be performed. The sample size
was set at a level consistent with prior human studies
involving arabinogalactan and the immune system
[16-18].
Methods
Investigational products
The proprietary arabinogalactan product ResistAid™,
supplied by Lonza Ltd, Switzerland, contains
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Arabinogalactan is a highly branched polysaccharide
that is composed of galactose units and arabinose units
in the approximate ratio of 6:1[7]. ResistAid™ is a fine,
dry, light brown powder with a neutral taste that dis-
solves quickly in water or juice. ResistAid™ is produced
via a water extraction patented process (US 5756098; EP
86608), in accordance with Hazard Analysis and Critical
Control Points (HACCP) standards and in compliance
with the monograph in the Food Chemicals Codex. The
Good Manufacturing Practices (GMP’s) used during
manufacturing are audited by the American Institute of
Baking. The Larch arabinogalactan used in the Resis-
tAid™ product has been designated as Generally Recog-
n i z e da sS a f e( G R A S )w i t ht h eU SF D A( G R A SN o t i c e
Nos. GRN000047 and GRN000084).
The placebo was maltodextrin (Maltrin M100, Grain
Processing Corp., USA). The test product and the pla-
cebo were administered by mixing the powders into a
beverage of the subject’s choice. The subjects were
advised to take their dosage (4.5 g) once a day in the
morning with breakfast. They began taking their
assigned powder on Day 1 and continued over the entire
72 day study period.
Subjects
Subjects between the ages of 18 and 65 were recruited
for the study in the usual manner (subject database and
community advertisements). Subjects were phone-
screened prior to scheduling a screening visit.
Subjects were included if they were 18-65 years of age,
had a Body Mass Index (BMI) ≥ 18 kg/m
2 and ≤ 30 kg/
m
2 at screening, agreed to all study visits and visit pro-
cedures, agreed to use approved forms of birth control,
and agreed not to initiate/change any exercise or diet
programs during the study. Subjects were excluded if
they had previously had the pneumococcal vaccine, had
any major systemic, inflammatory or chronic disease,
had any active infection or infection in the past month
requiring antibiotics or anti-viral medication, used
immunosuppressive drugs in the prior 5 years, were
known to have alcohol or drug abuse, were pregnant or
lactating or had any medical condition which in the opi-
nion of the investigator might interfere with the sub-
ject’s participation in the trial.
Study Design
The study was a randomized, double-blind, placebo-con-
trolled, parallel group trial with an active investigational
period of 72 days. The objective was to assess the
immunomodulatory effect of the arabinogalactan pro-
duct on selective markers of immune function following
antigenic challenge by the pneumococcal vaccine. The
primary endpoints were 7 different pneumococcal IgG
antibodies. The secondary objective was to determine
whether the arabinogalactan product would stimulate
other arms of the immune system to which there was
no direct antigenic stimulus. Secondary endpoints
included salivary IgA, white blood cell counts, comple-
ment (C3 and C4) and inflammatory cytokine levels.
The study was conducted at the Staywell Research clini-
cal research site located in Northridge, CA and was
designed and managed by the Medicus Research Con-
tract Research Organization (CRO) also in Northridge,
CA. IRB approval was obtained prior to the initiation of
any study activities (Copernicus Group IRB, Cary, NC).
Subjects meeting all of the inclusion criteria and none
of the exclusion criteria for this study were randomly
assigned to receive either the arabinogalactan or pla-
cebo. Double-blinding was ensured by the use of identi-
cal opaque sachets, outer packaging, labelling and color
for both investigational products (arabinogalactan and
placebo). Unblinding of the entire research team, includ-
ing data analysis team did not occur until after the ana-
lysis was completed; subjects were blinded throughout
the trial.
The study began in August 2008 (first subject in) and
lasted until December 2008 (last subject completed).
The subjects in the study came to the research clinic for
a total of 5 visits (V1-V5) over 72 days. Subjects took
the first dose of assigned study product at the screening
visit (V1-Day 0) and continued to take them over the
entire study. They received the 23-valent pneumococcal
vaccine (Pneumovax® 23, Merck and Co., Inc., USA) at
the vaccine visit which took place 30 days after they
began taking the product or placebo (V2-Day 30). They
came in for safety monitoring the day immediately fol-
lowing the vaccine (V3-Day 31) to observe the reaction
at the vaccine administration site. Then subjects
returned 21 days after vaccine (V4-Day 51) and finally
42 days after vaccine administration (V5-Day 72). On
study visits, blood, urine and saliva were collected and
subjects were queried regarding any change in health
status. Additionally, they were assessed for compliance
by interview, diary, and through the return of unused
study product sachets.
The most potentially immunogenic pneumococcal
antibodies (Ab) were determined in consultation with
the UCLA Vaccine Center (Torrance, CA, USA) as the
antibodies most likely to respond to vaccination with
the 23-valent pneumococcal vaccine. These antibodies
included 4, 6B, 9V, 14, 18C, 19F, and 23F. Salivary IgA
was measured to monitor for non-specific effects on the
adaptive immune system using immuno-array assays
with a minimum sensitivity of 1.0 μg/ml. Other markers
of immune function were chosen to represent the innate
arm of the immune system including white blood cell
counts (totals and subtypes), inflammatory cytokines,
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immuno-turbidimetric methodology. Analysis of inflam-
matory cytokine levels were performed using sandwich
immunoassay (Affymetrix, San Diego, CA, USA). Safety
monitoring included: body temperature, blood pressure,
heart rate, physical exam, urinalysis, complete blood
counts (CBC) and a comprehensive metabolic panel
(CMP) including kidney and liver function tests.
Analyses
Excel 2003 (Microsoft Corp, Redmond WA, USA), was
used for data entry, validation, restructuring, calculating
changes in variables over time, reorganizing and refor-
matting results, and preparing graphs. Statistical ana-
lyses were performed using SPSS Base System ver. 17
(SPSS Inc., Chicago IL, USA).
Data was analyzed using paired sample t-tests for within
subject means comparisons, independent sample t-tests
for between group comparisons (placebo vs. the active
groups individually). Difference scores for both within and
between group comparisons (placebo vs. the active groups
individually) were analyzed using appropriate t-tests. Ana-
lysis was completed before the blinding code was broken.
Results
Subjects
Sixty five (65) subjects were screened in person at the
research clinic and 53 qualified for randomization at the
screening visit (V1). Of the 53, 8 did not return for V2
and therefore a total of 45 subjects were included in the
intent-to-treat analysis. The subject baseline characteris-
tics are given in Table 1.
Pneumococcal IgG antibodies
Pneumococcal IgG antibody subtypes 4, 6B, 9V, 14, 18C,
19F, and 23F were measured on Days 0 (V1), 51 (V4),
and 72 (V5). There were no significant differences
between the groups at baseline (Day 0).
Pneumococcal IgG levels increased from baseline in
response to the vaccine as expected. Supplementation
with the arabinogalactan product caused a significantly
greater increase from baseline in pneumococcal IgG
antibody subtypes 18C and 23F at both 51 and 72 days
(Table 2). Mean values between groups were also signifi-
cantly greater in the arabinogalactan group for both
days 51 and 72 for these two subtypes (Table 3).
Change scores from baseline and mean values were
greater in the arabinogalactan group than placebo for
most time points in Ab subtypes 4, 6B, 9V, and 19F,
but these differences did not reach statistical
significance.
Salivary IgA
Salivary IgA levels in the placebo group were 146 ±
109 mg/dl at baseline (Day 0). There were no significant
changes from Day 0 to Days 51 or Day 0 to Day 72 in
either group. There were also no significant differences
in the mean values between groups.
White blood cells
The mean total white blood cell count was 6.50 ± 1.46 ×
1000/μl in the placebo group at baseline (Day 0). Com-
parisons between the arabinogalactan and placebo
groups on Days 0, 30, 31, 51 or 72 found no significant
differences in total white blood cell counts. The change
from baseline Day 0 to Day 72 was significantly greater
in the arabinogalactan group than the placebo group
(0.38 ± 0.79 compared to 0.15 ± 1.33; p = 0.045).
Differential analysis of white blood cells determined
that the levels at baseline were as follows: neutrophils
63.1 ± 5.3, lymphocytes 28.4 ± 6.0, monocytes 6.9 ± 1.9,
eosinophils 1.6 ± 1.5 and basophils 0.33 ± 0.56 (mea-
sured as a percent of total white blood cells). There
were no significant differences in lymphocyte, neutro-
phil, monocyte, or basophil counts when comparing
mean values between groups at any time point. When
comparing change from baseline at each time point,
there were no differences between groups for lympho-
cytes, neutrophils, or monocytes. Change from baseline
comparisons for basophils revealed a statistically signifi-
cant, but clinically insignificant increase in numbers in
the placebo group compared to the arabinogalactan
group when comparisons were made between Day 0 and
Day 72 (0.21 ± 0.72 placebo compared to 0.09 ± 0.54
arabinogalactan; p = 0.042).
Eosinophil counts were different between groups on
Day 30 (2.81 ± 2.04 vs 1.46 ± 0.98; p = 0.006) and on
Day 51 (3.24 ± 2.12 vs 1.83 ± 1.55; p = 0.014) with
higher numbers in the arabinogalactan group. There
was a larger increase in cell number (change) from base-
line to Day 31 (0.14 ± 1.39 vs 0.83 ± 0.72; p = 0.035)
and from baseline to Day 51 (0.48 ± 1.69 vs 0.20 ± 0.66;
p = 0.006) in the arabinogalactan group.
Complement
The levels of complement C3 and C4 at Day 0 were
125 ± 23 and 28 ± 10 mg/dl, respectively. Comparisons
of means and changes from baseline for complement
(C3, C4) levels between the arabinogalactan and placebo
groups were not significantly different.
Table 1 Subject Demographics
ResistAid
(™) Placebo
N 21 24
Male 9 (42.9%) 16 (66.7%)
Female 12 (57.1%) 8 (33.3%)
Age (range) 33.52 (19-62) 38.25 (20-64)
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Comparison of cytokine levels between groups found no
significant differences in means for epithelial neutrophil-
activating peptide (ENA)-78, eotaxin, granulocyte mono-
cyte colony stimulating factor (GM-CSF), interferon-
gamma (IFNg), interleukin (IL)-10, IL-12P40, IL-1RA,
IL-2, IL-4, IL-5, IL-6, IL-8, monocyte chemotactic pro-
tein (MCP)-1, MCP-3, platelet-derived growth factor
(PDGF)-BB or tumor necrosis factor (TNF)-alpha.
When comparing the cytokine change from baseline
values between groups, only the IL-6 change from Day
30 to Day 31 showed an increase in the arabinogalactan
g r o u pc o m p a r e dt ot h ep l a c e b og r o u p .T h ec h a n g ei n
the arabinoglactan group was from a mean of 17.8 ± 7.7
to 19.8 ± 7.7 pg/ml (+1.9), compared to a change from
50.1 ± 113.8 to 48.7 ± 112.5 pg/ml for the placebo
group (-2.4) (p = 0.046). This was most likely in
response to the vaccine which was administered on Day
30.
Safety
No serious adverse events were reported during this
study. There were nine mild adverse events in the pla-
cebo group (erythema at injection site (1), sore throat
(2), nasal congestion (3), headache (2), and abdominal
pain (1). There were no adverse events in the active
group. All adverse events were followed by the medical
staff at the research clinic.
Discussion
The results of this pilot study suggest that the arabino-
galactan preparation had a selective immunostimulating
effect on acquired or adaptive immunity, as shown in
t h ei n c r e a s ei na n t i b o d i e sw i t hout any clinically signifi-
cant effects on total white blood cells, cytokines or com-
plement. Thus it is possible that rather than acting as a
general immunostimulant, arabinogalactan acted in a
specific manner. The caveat to this statement is that
these results are preliminary and there are confounding
variables to consider.
Variables that affect the immune response to vaccines
include age, gender, race and genetic characteristics[19].
O n eo ft h eg o a l so ft h i sp i l o ts t u d yw a st od e t e r m i n e
the effect of the intervention on a relatively broad popu-
lation. As such, the study population included males
and females from age 18 to 65. The randomization
scheme was sequential and therefore the gender of sub-
jects was not matched in advance. As gender and age
Table 2 Effects of the 23-valent vaccine on Pneumococcal IgG antibodies
Antibody subtype Day 0
Mean ± SD
Day 51
Mean ± SD
Day 72
Mean ± SD
Change
Days 0-51
Change
Days 0-72
Type 4 0.45 ± 0.64 2.21 ± 3.15 5.84 ± 7.35 0.023 0.042
Type 6B 0.95 ± 1.51 5.18 ± 6.64 5.19 ± 7.06 0.001 0.020
Type 9V 1.32 ± 4.10 6.07 ± 7.34 5.08 ± 5.25 0.129 0.095
Type 14 1.79 ± 2.56 9.91 ± 8.54 8.86 ± 8.59 0.000 0.006
Type 18C 0.72 ± 1.35 5.06 ± 5.80 4.93 ± 5.26 0.018 0.006
Type 19F 1.10 ± 2.94 7.02 ± 7.28 6.65 ± 7.26 0.011 0.015
Type 23F 1.08 ± 1.87 4.32 ± 4.62 4.55 ± 5.23 0.017 0.006
Increases in levels of antibody subtype as observed in the placebo group (n = 24) following inoculation with the 23-valent pneumococcal vaccine which took
place on Day 30. Data are means (μg/dl) ± standard deviations on Days 0, 51 and 72. P-values for the changes between baseline and days 51 and 72 are in the
right hand columns.
Table 3 Pneumococcal IgG types 18C and 23F - Comparisons between ResistAid
(TM) and Placebo Groups
Day 0
Mean ± SD
Day 51
Mean ± SD
Day 72
Mean ± SD
Change
Day 0-51
Change
Day 0-72
Type 18C
ResistAid™ (n = 21) 1.49 ± 3.00 9.57 ± 7.96 9.10 ± 7.53 8.08 ± 7.12 7.61 ± 6.81
Placebo (n = 24) 0.72 ± 1.35 5.06 ± 5.80 4.93 ± 5.26 4.34 ± 5.10 4.22 ± 4.69
Comparison (p-value) 0.061 0.006 0.008 0.033 0.012
Type 23F
ResistAid™ (n = 21) 0.74 ± 0.93 7.07 ± 7.41 7.02 ± 7.31 6.33 ± 7.36 6.28 ± 7.17
Placebo (n = 24) 1.08 ± 1.87 4.32 ± 4.62 4.55 ± 5.23 3.24 ± 4.28 3.46 ± 4.24
Comparison (p-value) 0.059 0.002 0.041 0.001 0.003
Levels of antibody subtypes 18C and 23F in the ResistAid™ and placebo groups are given as means (μg/dl) ± standard deviations on Days 0, 51 and 72 and
changes from Day 0. Inoculation with the 23-valent pneumococcal vaccine took place on Day 30. P-values are comparisons between groups and comparisonso f
changes from Day 0 in the two groups.
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founding variable should be looked at in future studies.
This study was an exploratory investigation into the
effects of arabinogalactan with the goal of determining
whether further studies are warranted. The result is that
further studies with larger populations are indicated to
clarify and potentially expand upon the effects of arabi-
nogalactan on antibody production.
The suggestion that arabinogalactan might have a
selective effect on the immune system is preliminary but
p r o m i s i n g .T h ei m m u n es y s t e me n t a i l sac o m p l e x
matrix of responses to protect the body from pathogens
a n dt o x i n s .T h ei n n a t ei m m u n es y s t e mi n v o l v e st h e
rapid recruitment and upregulation of neutrophils,
monocytes, macrophages, complement factors, cytokines
and antimicrobial peptides to the site of infection. The
innate response is the first line of host defense and the
adaptive response follows a few days later. While the
innate and adaptogenic arms of the immune system are
often described as separate, they often act together in a
synergistic manner[20]. In addition to antibodies, the
variables tested in this study included salivary IgA, white
blood cell counts (lymphocytes, neutrophils, monocytes,
basophils and eosinophils), complement C-3 and C-4 as
well as numerous cytokines. Additionally, suggestions of
changes were observed in IL-6 levels and in eosinophil
counts. IL-6 has immunostimulatory properties and
eosinophils play a role in allergic responses. The clinical
significance of these findings is unknown at this time.
Additional measurements for future studies could
include a breakdown of lymphocytes into subtypes, mea-
suring natural killer (NK) lymphocytes and NK-T cells.
NK cells are a heterogeneous population of innate
T cells that have attracted interest because of their
potential to regulate immune responses to a variety of
pathogens and NK-T cells function as a bridge between
innate and adaptive immunity[20].
Arabinogalactan was given for 30 days prior to vacci-
nation and administration was continued throughout
the study. The 30 days time period was chosen because
a previous clinical trial studying the effect of arabinoga-
lactan and echinacea preparations on the immune sys-
tem observed a positive effect following treatment for
this period of time[16].
This is the first human study to demonstrate an effect
by Larch arabinogalactan on immunoglobulin levels. No
effect on IgG antibody levels was observed in another
s t u d yw h e r e i nt h es u b j e c t sw e r ea d m i n i s t e r e d1 . 5g
larch arabinogalactan per day for four weeks[16]. This
study utilized a larger dose (4.5 g per day), longer
administration time (10 weeks) and the vaccine as a
standardized antigenic challenge all of which appear to
have been useful in delineating a difference between the
proprietary arabinogalactan extract and placebo.
Conclusions
The proprietary arabinogalactan extract (ResistAid™)
tested in this randomized, double-blind, placebo-con-
trolled, parallel-group study, increased the antibody
response of healthy volunteers to the 23-valent pneumo-
coccal vaccine compared to placebo. The proprietary
arabinogalactan product was administered safely in this
study in a dose of 4.5 g perd a yf o ra p p r o x i m a t e l y
10 weeks. This was a pilot study that demonstrated pro-
mising effects and further studies with larger popula-
tions are indicated which may demonstrate additional
effects of arabinogalactan on the immune system.
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